CHRIS as a FAMILY PERSON
Chris’s family is her fulcrum and everything that makes Chris the person she is today, revolves around that fact. From spending quality time at the beach with her husband and her 3 children near her home, to quiet evenings spent with a glass of good wine and even better food – this makes her complete.
Chris is married to Edwin. Together they have two teenage daughters, Esmée and Danique, and one teenage son, Loran. In her spare time, she loves to run, walk, read and sun bathing.
CHRIS as an ACTIVE PHILANTHROPIST
Chris is an active philanthropist. In her spare time, together with her international, interdisciplinary colleagues and friends, she is running and financing the Impaqtt Foundation that aims to transform the adverse event approach strategy in the world so more patients can complete the cancer treatment as planned.
It is time to change how the world treats the side effects of targeted therapy and immuno-oncology in cancer. More CARE and Less BURDEN. Founded in 2012, the Impaqtt Foundation is an independent foundation helping those suffering from side effects of targeted therapy & immuno-oncology. The headquarter is in The Netherlands and they maintain an international network in over 15 countries.
Through her partnership with the Impaqtt Foundation, Chris has provided countless lectures for patients and patient organizations, developed tools that support the Patients Drug Success immediately, and provided consultations for free to those in need.
Help Chris to treat the side-effects so more patients can maintain as long as needed on their oncology drug.
Spread the word on social media through the #MakeIMPAQTT hashtag via Twitter, Facebook and LinkedIn. And join the Impaqtt Foundation.
Support the mission of the Impaqtt Foundation to limit adverse events of immuno-oncology and targeted therapy: #MakeImpaqtt #ProlongLife #SafeMillions #SpreadTheWord #DonateNow
CHRIS as an ENTREPRENEUR
What makes CB Boers ORG. is two folds.
One is the culture that has been built based on a “Fulfill Your Potential” philosophy that means the more successful you become with oncology drugs, the more successful she becomes with her own potential in supporting you.
Second is her #FamilyFirst mantra. CHRIS treats you as if you were her family and as cliché as it may sound, it’s what has really differentiated her from the rest of the competition.
CHRIS as a STRATEGIST
Chris loves coaching & mentoring leaders throughout the entire Drug Success Chain. She teaches how to achieve Ultimate Drug Success through target strategies and techniques. Chris’s teachings are always practical, to the point and effective.
One of her unique zones are accelerating systems. Tiny changes take so little time and not much money but triggers Ultimate Drug Success.
All her successes have been created with the 80/20 rule and reverse-engineering in mind. Both go hand-in-hand. Her Target Strategy is revolutionary. Apply a triple diagnostic approach on adverse events and you will get the same results as with the triple approach in cancer diagnosis.
Why you should work with CHRIS:
- In general, Chris’s patients do not have to interrupt their treatment due to unmanaged adverse events.
- In general, Chris’s patients maintain as long as needed on their drug since their adverse events are managed systematically and at an early stage.
- If you’re looking for extraordinary levels of getting the best out of oncology drugs… Chris will do whatever it takes to guide you there.
- Chris knows how to simplify big topics and make them actionable.
- Chris knows how to inspire people to go for their best.
Why Chris wants to work with you:
Because Chris believes that you as a leader are the one who really can make a difference in this world.
- because you’re committed
- because you’re determined
- because you’re not afraid to fail
- because you do whatever it takes…
- because you’re fun to work with!
If you are eager to get the best out of oncology drugs…
The world needs you!
CHRIS as a KEYNOTE SPEAKER
Chris is practice changing as Keynote Speaker.
Chris loves people and its evident in everything she does that she wants to make a difference and leave an impact on the world.
What better way of achieving this than sharing her message on stage with you?
Chris has taken her speaking career from being relatively unknown to now speaking on international stages worldwide to very large audiences.
The powerful message of her success is what holds her audiences enthralled from start to finish.
CHRIS as a TRAINER
Chris realized over time, that something that started out as being just another item in her daily schedule, had turned into something she enjoyed and had actually developed into a passion.
This led her to educating herself to one of the highest standards in Drug Success Strategies worldwide.
CHRIS as a COACH & MENTOR
Chris takes your coaching very seriously. She coaches about achieving Ultimate Drug Success by digging deep into the 7 Pillars of Drug Success, the 7 Success Habits, your Mindset & Strategies. She doesn’t coach from a manual or a script. Every coaching program is individually matched based on experience, needs and desired outcome.
She actually spends 90% of her time doing what she teaches because how can you expect a coach to effectively teach you how the real world works if she is not doing it her selves. The area of cancer treatments changes so rapidly these days and the rhetoric of how it used to work in the old days doesn’t work in today’s cancer practice.
Her Fulfil Your Potential and #FamilyFirst culture and philosophy has led her to coach various disciplines; from global directors, CEO’s, medical directors, product specialists to physicians, nurses, data managers, patients, and their support system. Every stakeholder involved with the safety profile of cancer drugs and their side effects can be coached effectively on their own level. She has achieved successes all over the world. Results don’t lie.
CHRIS as a CLINICIAN SCIENTIST
Chris is a Clinician-Scientist who conducts clinical research on a variety of conditions. Immuno-oncology & targeted therapy in cancer have her upmost attention.
Chris is very experienced in all aspects of clinical research including study protocol writing, case report form development, tool development, tool translation, tool validation, data analysis, data interpretation, abstract preparation, publication preparation and presentation.
Chris provides special attention to management of immune-oncology & targeted therapy associated mucocutaneous adverse events. The mucocutaneous adverse events are frequent in those treated with those agents, and they can lead to a significant impact on health related quality of life, as well as modifications in lifesaving antineoplastic therapy. The need to address these poorly understood mucocutaneous adverse events sparked her interest and is her ongoing PhD project. The specific goal of her research program is to develop, translate, validate and implement healthcare provider assessment tools and patient reported outcome measures (PRO), and find and implement practical measures to improve health related quality of life so patients can receive immune-oncology & targeted anticancer therapy full dose on time.
Investigating in Early Phases Research
Chris develops assessment, grading, and education tools, and generates treatment recommendations for immuno-oncology & targeted therapy-associated adverse events. In addition, she educates why it is so, so important to start researching adverse events already in early phases of research.
03/1998 – 2006 Institutional Review Board (IRB) Waterland Hospital, Purmerend, The Netherlands
06/2001 – 09/2007 Institutional Review Board (IRB) Medical Ethics Review Committee “METC Noord Holland”, Alkmaar, The Netherlands
06/2008 – 06/2013 Founder and chair of the Nursing Advisory Board BOOG-PIVOTAL. BOOG is the Dutch Breast Cancer Trialists’ Group (Borstkanker Onderzoek Groep). The Nursing Advisory Board provides practical and logistical advice about the implementation of BOOG trials in clinical settings. The group also participates in the development of nursing protocols and in the review of study information for patients. Chris was chair of the Nursing Advisory Board BOOG-PIVOTAL till June 2013 and is still an BOOG member.
02/2007 – 09/2012 Oncology research coordinator at the Oncology Clinical Trials Office of the Waterland Hospital, Purmerend, The Netherlands
04/2008 – present PhD Program
Chris as an AUTHOR
Becoming an Drug Success Master in today’s challenging health care is not easy but Chris never gave up on herself to achieve the goals that she had set for her life. This TARGET System book is one of those goals.
Taking the knowledge she has learnt over the years and putting pen to paper she has written her first book that gives you the insight into her journey to becoming a Drug Success Master and what she had learnt along the way from all the very successful adverse event masters, coaches, and mentors that she has been exposed to.
Articles, Abstracts & Posters
|2007||Boers CB: EGFR-inhibitors: Do you give the right advices? Skin reactions by epidermal growth factor receptor inhibitors [EGFR-remmers: geef jij de juiste adviezen? Huidreacties door epidermale groeifactor receptor-remmers]. Oncologica. 2007;2:36-39|
|2008||Koldenhoff JJ, Boers-Doets CB: Book Chapter 4.9 Skin Toxicity; in Huisman C, Mallo H, van Riel C, Hulshoff A, van Steijn J, Immuno-/targeted therapy in solid and hematology care [Immuno-/targeted therapie in de hemato-/oncologische zorg]. ISBN: 9789035230064. Reed Elsevier. 2008;78-87|
|2009||Boers CB, Galimont AFS, Gelderblom AJ: Skin reactions due to Erbitux treatment, patient information [Huidreacties bij een behandeling met Erbitux] provided by Merk Serono Netherlands 2009, revised edition of the patient information cards Skin reaction October 4th 2006|
|2008||Ouwerkerk J, Boers-Doets CB: Focus on eye changes [Oog voor oogafwijkingen]. Nursing. July/August, 2008;22-24|
|2009||Boers-Doets CB, Langenhoff JM, Brakenhoff JAC, et al.: Dermatological side effect interventions for targeted cancer treatment untangled: A systematic review. EJC supplements. 2009;7:185, poster presentation|
|2010||Ouwerkerk J, Boers-Doets CB: Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010;14(4):337-49. Epub 2010 May 23|
|2010||Boers-Doets CB, Ouwerkerk J, Schrama NAWP, Galimont AFS: Management skin-, hair-, nail-, and eye reactions targeted therapy: comprehensive – not complex [Management huid-, haar- nagel- en oogreacties targeted therapie: veelomvattend – maar niet complex]. Oncologica. 2010;2: 21-24|
|2011||Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x. Review.|
|2011||Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1. Review.|
|2012||Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A: Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group. Eur J Oncol Nurs. 2012 Apr;16(2):172-84. Epub 2011 Jun 8.|
|2011||Boers-Doets C, Lacouture M, Langenhoff J, van Zuuren EJ, Stijnen T, Brakenhoff J, Ouwerkerk J, Galimont A, Bro W, Nortier H: Interventions for skin reactions associated with targeted anticancer treatments. Cochrane Database of Systematic Reviews. 2011, Issue 7. Art. No.: CD009236. DOI: 10.1002/14651858.CD009236.|
|2012||Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist. 2012;17(1):135-44. doi: 10.1634/theoncologist.2011-0111. Epub 2011 Dec 29. Review.|
|2012||Raber-Durlacher JE, Boers-Doets CB, de Graeff A: Oral complaints; Side effects of new targeted cancer therapies [Mondklachten; Bijwerkingen van nieuwe doelgerichte kankertherapieen]. Tandartspraktijk. 2012;33(9):26-31.|
|2013||Boers-Doets CB: Skin toxicities caused by targeted therapies. Cancer World. 2013 March-April: 37-43.|
|2013||Boers-Doets CB, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. Eur J Oncol Nurs. 2013 Dec;17(6):802-7. doi: 10.1016/j.ejon.2013.03.004. Epub 2013 Apr 6.|
|2013||Boers-Doets CB, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer. 2013 Jul;21(7):1919-26. doi: 10.1007/s00520-013-1752-4. Epub 2013 Feb 17.|
|2013||Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013 Oct;21(10):2933-48. doi: 10.1007/s00520-013-1896-2. Epub 2013 Aug 14. Review.|
|2013||Boers-Doets CB, Lalla RV: The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis. Support Care Cancer. 2013;21 (S1),S140|
|2013||Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, Bossi P, Escalante C, Brennan MT; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer. 2013 Nov;21(11):3243-54. doi: 10.1007/s00520-013-1821-8. Epub 2013 May 2. Review.|
|2013||Boers-Doets CB, Lacouture ME: Dermatologic Events in Oncology: How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life. http://issuu.com/ascopost/docs/tap_vol_4_issue_20. ASCO Post. 2013 Dec 15;4(20):70-71|
|2013||Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141. Review.|
|2013||Boers-Doets CB, Kaptein AA, Brakenhoff JAC, Nortier, JWR, Gelderblom H: Targeted therapy associated mucocutaneous reactions – the BeCet and the COMTT study [Doelgerichte therapie geassocieerde mucocutane bijwerkingen – de BeCet en de COMTT studie]. NTvO. 2013;(10)8:343-47.|
|2013||De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A, Cremolini C. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014 Mar;22(3):837-46. doi: 10.1007/s00520-013-2085-z. Epub 2013 Dec 14. Review.|
|2014||Kaehler KC, Boers-Doets CB, Lacouture ME, Hauschild A. Chapter 21: Miscellaneous Reactions. In Lacouture ME, et al: Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients. Wiley-Blackwell. ISBN: 9780470621882. Published: 31 January 2014. p.224-33.|
|2014||Boers-Doets CB. The Target System – Approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. First edition. 2014 IMPAQTT. ISBN/EAN: 978-94-92070-00-5|
|2014||Bryce J, Boers-Doets CB. Non-rash dermatologic adverse events related to targeted therapies. Semin Oncol Nurs. 2014 Aug;30(3):155-68. doi: 10.1016/j.soncn.2014.05.003.|
|2015||Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up†. Ann Oncol. 2015 Sep;26 Suppl 5:v139-51. doi: 10.1093/annonc/mdv202. Epub 2015 Jul 4.|
|2015||Clabbers JM, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJ, Kaptein AA. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.|
|2015||Ruiz JN, Belum VR, Boers-Doets CB, Kamboj M, Babady NE, Tang YW, Valdez TA, Lacouture ME. Nasal vestibulitis due to targeted therapies in cancer patients. Support Care Cancer. 2015 Aug;23(8):2391-8. doi: 10.1007/s00520-014-2580-x. Epub 2015 Jan 22.|
|2015||Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer. 2015 Aug;23(8):2231-44. doi: 10.1007/s00520-014-2564-x. Epub 2015 Jan 7.|
|2015||R.V. Lalla, C. B. Boers-Doets ESMO Handbook on Rehabilitation Issues During Cancer Treatment and Follow-Up. Chapter 5 – Mucocutaneous Changes. http://oncologypro.esmo.org/Publications/Handbooks/Rehabilitation-Issues-During-Cancer-Treatment-and-Follow-Up|
Read more about Chris’s Work
Facebook is by far her favorite social media platform. Why? Because it’s easy to use, quick, reliable and is becoming more and more media rich. Be sure to like her Official Facebook Page, because she does share things there that she don’t anywhere else – and don’t forget to choose ‘Get Notifications’ to stay up to date! Ask Chris questions and provide feedback. Click the button below to follow her immediately and easily.
If you want to stay tuned and want to get notified about tips, trends, articles, video’s and events about how to achieve ultimate drug success; with special attention to immuno-oncology & targeted therapy in cancer you can also subscribe to her Drug Success Nuggets.